Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Taming the SARS-CoV-2-mediated proinflammatory response with BromAc®

Ferreira et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1308477
Dec 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
14th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000034 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
In vitro study of peripheral blood cells from 9 healthy donors showing reduced proinflammatory cytokines, growth factors, and regulatory cytokines; decreased neutrophils and monocytes; and increased HLA-DR expression on monocytes with BromAc (bromelain plus acetylcysteine) treatment in the presence of inactivated SARS-CoV-2. BromAc demonstrated anti-inflammatory and immunomodulatory effects against SARS-CoV-2-induced immune responses.
6 preclinical studies support the efficacy of N-acetylcysteine for COVID-19:
NAC may be beneficial for COVID-19 by replenishing glutathione stores and reinforcing the glutathione peroxidase-4 pathway to inhibit ferroptosis, an oxidative stress-induced cell death pathway implicated in COVID-19 Yuan. N-acetylcysteine shows dose-dependent inhibition of SARS-CoV-2 Akhter, La Maestra, shows anti-inflammatory and immunomodulatory effects against SARS-CoV-2-induced immune responses in combination with bromelain Ferreira, and suppressed virus-induced reactive oxygen species and blocked viral replication in a humanized mouse model and in human lung cells Frasson.
Ferreira et al., 13 Dec 2023, Brazil, peer-reviewed, 13 authors. Contact: jreis@icb.ufmg.br, reisjordana@gmail.com, sarah@mucpharm.com, david@mucpharm.com.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperN-acetylcys..All
Taming the SARS-CoV-2-mediated proinflammatory response with BromAc®
Geovane Marques Ferreira, Felipe Alves Clarindo, Ágata Lopes Ribeiro, Letícia Gomes-De-Pontes, Luciana Debortoli De Carvalho, Olindo Assis Martins-Filho, Flávio Guimarães Da Fonseca, Mauro Martins Teixeira, Adriano De Paula Sabino, Mathew Suji Eapen, David L Morris, Sarah J Valle, Jordana Grazziela Alves Coelho-Dos-Reis
Frontiers in Immunology, doi:10.3389/fimmu.2023.1308477
Introduction: In the present study, the impact of BromAc®, a specific combination of bromelain and acetylcysteine, on the SARS-CoV-2-specific inflammatory response was evaluated. Methods: An in vitro stimulation system was standardized using blood samples from 9 healthy donors, luminex assays and flow cytometry were performed. Results and discussion: BromAc® demonstrated robust anti-inflammatory activity in human peripheral blood cells upon SARS-CoV-2 viral stimuli, reducing the cytokine storm, composed of chemokines, growth factors, and proinflammatory and regulatory cytokines produced after short-term in vitro culture with the inactivated virus (iSARS-CoV-2). A combined reduction in vascular endothelial growth factor (VEGF) induced by SARS-CoV-2, in addition to steady-state levels of platelet recruitment-associated growth factor-PDGFbb, was observed, indicating that BromAc® may be important to reduce thromboembolism in COVID-19. The immunophenotypic analysis of the impact of BromAc® on leukocytes upon viral stimuli showed that BromAc® was able to downmodulate the populations of CD16+ neutrophils and CD14+ monocytes observed after stimulation with iSARS-CoV-2. Conversely, BromAc® treatment increased steady-state HLA-DR expression in CD14 + monocytes and preserved this activation marker in this subset upon iSARS-CoV-2 stimuli, indicating improved monocyte activation upon BromAc® treatment. Additionally, BromAc® downmodulated the iSARS-CoV-2-induced production of TNF-a by the CD19+ B-cells. System biology approaches, utilizing comprehensive correlation matrices and networks, showed distinct patterns of connectivity in groups Frontiers in Immunology frontiersin.org 01
Ethics statement The studies involving humans were approved by Ethics Committee of Universidade Estadual de Santa Cruz (UESC) and Federal University of Minas Gerais (UFMG). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Author contributions Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fundacão de Amparo à Pesquisa de Minas Gerais (FAPEMIG, APQ-01499-21), Conselho Nacional de Desenvolvimento Cientıfco e Tecnoloǵico (CNPq MCTI/CNPQ/Universal), EMBRAPII (Process # 30275) and Coordenacão de Aperfeicoamento de Pessoal de Nıvel Superior (CAPES). FF, OM, MT, and JC-d-R received PQ fellowships from CNPq. This work was also funded by extramural resources from Mucpharm Pty Ltd (AU). OF participated in the fellow program supported by the Universidade do Estado do Amazonas (PROVISIT N°005/2023-PROPESP/UEA). Conflict of interest SV and DM are shareholders of Mucpharm Pty Ltd. and provided scientific input on the protocol and design of the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Mucpharm Pty Ltd. The funder had the following..
References
Abdelrahman, Abd-Elrahman, Bakheet, Persistence of symptoms after improvement of acute COVID-19 infection, a longitudinal study, J Med Virol, doi:10.1002/jmv.27156
Akhter, Queŕomès, Pillai, Kepenekian, Badar et al., The combination of bromelain and acetylcysteine (BromAc) synergistically inactivates SARS-CoV-2, Viruses, doi:10.3390/v13030425
Atanasova, Reznikov, Strategies for measuring airway mucus and mucins, Respir Res, doi:10.1186/s12931-019-1239-z
Barnes, Adrover, Baxter-Stoltzfus, Borczuk, Cools-Lartigue et al., Targeting potential drivers of COVID-19: Neutrophil extracellular traps, J Exp Med, doi:10.1084/jem.20200652
Barth, Guseo, Klein, In vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humans, Eur J Med Res
Bateman, Dear, Thanacoody, Thomas, Eddleston et al., Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial, Lancet, doi:10.1016/S0140-6736(13)62062-0
Bösmüller, Traxler, Bitzer, Häberle, Raiser et al., The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation, Virchows Archiv, doi:10.1007/s00428-020-02881-x
Coelho Dos Reis, Ferreira, Lourenco, Ribeiro, ́l et al., Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19, Biomed Pharmacother, doi:10.1016/j.biopha.2022.112753
Darif, Hammi, Kihel, Idrissi Saik, Guessous et al., The proinflammatory cytokines in COVID-19 pathogenesis: What goes wrong?, Microb Pathog, doi:10.1016/j.micpath.2021.104799
Declercq, Leeuw, Lambrecht, Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent, Cytokine, doi:10.1016/j.cyto.2022.155934
Ekstedt, Piersiala, Petro, Karlsson, Kågedal et al., A prolonged innate systemic immune response in COVID-19, Sci Rep, doi:10.1038/s41598-022-13986-5
Fitzhugh, Shan, Dewhirst, Hale, Bromelain treatment decreases neutrophil migration to sites of inflammation, Clin Immunol, doi:10.1016/j.clim.2008.02.015
Goncalves, Da Mata, Lourenco, Ribeiro, ́l et al., Timeline kinetics of systemic and airway immune mediator storm for comprehensive analysis of disease outcome in critically ill COVID-19 patients, Front Immunol, doi:10.3389/fimmu.2022.903903
Gusev, Sarapultsev, Solomatina, Chereshnev, SARS-coV-2-specific immune response and the pathogenesis of COVID-19, Int J Mol Sci, doi:10.3390/ijms23031716
Hu, Huang, Yin, The cytokine storm and COVID-19, J Med Virol, doi:10.1002/jmv.26232
Huang, Wu, Hou, Jeng, Bromelain inhibits lipopolysaccharide-induced cytokine production in human THP-1 monocytes via the removal of CD14, Immunol Invest, doi:10.1080/08820130802083622
Jukema, Smit, Hopman, Bongers, Pelgrim et al., Neutrophil and eosinophil responses remain abnormal for several months in primary care patients with COVID-19 disease, Front Allergy, doi:10.3389/falgy.2022.942699
Kang, Lee, Jeon, Jo, Roles of interleukin-17 and th17 responses in COVID-19, J Bacteriol Virol, doi:10.4167/jbv.2021.51.3.089
Khan, Khan, Charles, Pratap, Naeem et al., Cytokine storm and mucus hypersecretion in COVID-19: review of mechanisms, J Inflammation Res, doi:10.2147/JIR.S271292
Kleef, Delohery, Bovbjerg, Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5, Pathobiology, doi:10.1159/000164070
Knight, Caricchio, Casanova, Combes, Diamond et al., The intersection of COVID-19 and autoimmunity, J Clin Invest, doi:10.1172/JCI154886
Knoll, Schultze, Schulte-Schrepping, Monocytes and macrophages in COVID-19, Front Immunol, doi:10.3389/fimmu.2021.720109
Li, Hilgenfeld, Whitley, Clercq, Therapeutic strategies for COVID-19: progress and lessons learned, Nat Rev Drug Discovery, doi:10.1038/s41573-023-00672-y
Liu, Lv, Liu, Li, Xie et al., Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19, Cell Res, doi:10.1038/s41422-020-00435-z
Lourda, Dzidic, Hertwig, Bergsten, Medina et al., High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19, Proc Natl Acad Sci, doi:10.1073/pnas.2109123118
Meyerholz, Reznikov, Influence of SARS-CoV-2 on airway mucus production: A review and proposed model, Vet Pathol, doi:10.1177/03009858211058837
Mohanty, Padhy, Das, Meher, Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202103_25442
Mokhtari, Afsharian, Shahhoseini, Kalantar, Moini, A review on various uses of N-acetyl cysteine citation, Cell Journal, doi:10.22074/cellj.2016.4872
Montazersaheb, Khatibi, Hejazi, Tarhriz, Farjami et al., COVID-19 infection: an overview on cytokine storm and related interventions, Virol J, doi:10.1186/s12985-022-01814-1
Muralidharan, Wyatt, Reid, SARS-coV-2 dysregulates neutrophil degranulation and reduces lymphocyte counts, Biomedicines, doi:10.3390/biomedicines10020382
Nasrollahi, Talepoor, Saleh, Vakili, Heydarinezhad et al., Immune responses in mildly versus critically ill COVID-19 patients, Front Immunol, doi:10.3389/fimmu.2023.1077236
Onken, Greer, Calingaert, Hale, Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro, Clin Immunol, doi:10.1016/j.clim.2007.11.002
Paho, Who, Pan American Health Organization, Update on variant of interest EG.5 and variant under surveillance BA
Potere, Buono, Caricchio, Cremer, Vecchiéa et al., Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications, EBioMedicine, doi:10.1016/j.ebiom.2022.104299
Proal, Vanelzakker, Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms, Front Microbiol, doi:10.3389/fmicb.2021.698169
Rodrıǵuez, Novelli, Rojas, Santis, Acosta-Ampudia et al., Autoinflammatory and autoimmune conditions at the crossroad of COVID-19, J Autoimmun, doi:10.1016/j.jaut.2020.102506
Salle, Coronavirus-induced autoimmunity, Clin Immunol, doi:10.1016/j.clim.2021.108694
Saraiva, Vieira, Garra, Biology and therapeutic potential of interleukin-10, J Exp Med, doi:10.1084/jem.20190418
Sharma, Vimal, Bromelain: an enzyme expanding its horizon from food to pharmaceutical industry, Curr Pharm Biotechnol, doi:10.2174/1389201024666230331115338
Tysnes, Maurert, Porwol, Probst, Bjerkvig et al., Bromelain reversibly inhibits invasive properties of glioma cells, Neoplasia, doi:10.1038/sj.neo.7900196
Valle, Akhter, Mekkawy, Lodh, Pillai et al., A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study, Eur J Surg Oncol, doi:10.1016/j.ejso.2019.10.033
Villadangos, Bryant, Deussing, Driessen, Lennon-Dumeńil et al., Proteases involved in MHC dass II antigen presentation, Immunol Rev, doi:10.1111/j.1600-065X.1999.tb01360.x
Vj, Illescas-Montes, Puerta-Puerta, Ruiz, Melguizo-Rodrıǵuez, SARS-CoV-2 infection: The role of cytokines in COVID-19 disease, Cytokine Growth Factor Rev, doi:10.1016/j.cytogfr.2020.06.001
Wang, Wong, Ouyang, Rutz, Targeting IL-10 family cytokines for the treatment of human diseases, Cold Spring Harb Perspect Biol, doi:10.1101/cshperspect.a028548
Wilk, Rustagi, Zhao, Roque, Martıńez-Coloń et al., A single-cell atlas of the peripheral immune response in patients with severe COVID-19, Nat Med, doi:10.1038/s41591-020-0944-y
Zhang, Qin, Li, Wang, Zhao et al., A novel scoring system for prediction of disease severity in COVID-19, Front Cell Infect Microbiol, doi:10.3389/fcimb.2020.00318
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit